Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2010
  • Online publication date: August 2011

4 - Screening for hypertensive disorders of pregnancy

Related content

Powered by UNSILO

References

1. VillarJ, SayL, GulmezogluAM, et al. Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In: MacLeanA, PostonL, WalkerJ, eds. Preeclampsia. London,RCOG Press. 2003;189–207.
2. NewmanRB, EddyGL. Association of eclampsia and hydatidiform mole: case report and review of the literature. Obstet Gynecol Surv 1988;43(4):185–90.
3. RobertsJM.Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16(1):5–15.
4. Conde-AgudeloA, VillarJ, LindheimerM. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104(6):1367–91.
5. MeekinsJW, PijnenborgR, HanssensM, McFadyenIR, van AssheA.A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101(8):669–74.
6. OlofssonP, LauriniRN, MarsalK.A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 1993;49(3):161–8.
7. CnossenJS, MorrisRK, ter RietG, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008;178(6):701–11.
8. PilalisA, SoukaAP, AntsaklisP, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11–14 weeks' gestation. Ultrasound Obstet Gynecol 2007;29(2):135–40.
9. SpencerK, CowansNJ, ChefetzI, TalJ, MeiriH.First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007;29(2):128–34.
10. CrispiF, LlurbaE, DominguezC, et al. Predictive value of angiogenic factors and uterine artery Doppler for early-versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;31(3):303–9.
11. StepanH, GeipelA, SchwartzF, et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008;198(2):175.e1–6.
12. ThanNG, PickE, BellyeiS, et al. Functional analyses of placental protein 13/galectin-13. Eur J Biochem 2004;271(6):1065–78.
13. NicolaidesKH, BindraR, TuranOM, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006;27(1):13–17.
14. ChafetzI, KuhnreichI, SammarM, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007;197(1):35.e1–7.
15. RomeroR, KusanoricJP, ThanNG, et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008;199(2):122.e1–11.
16. KogaK, OsugaY, YoshinoO, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88(5):2348–51.
17. MaynardSE, MinJY, MerchanJ, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111(5):649–58.
18. LevineRJ, MaynardSE, QianC, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350(7):672–83.
19. McKeemanGC, ArdillJE, CaldwellCM, HunterAJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191(4):1240–6.
20. AhmadS, AhmedA.Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95(9):884–91.
21. DvorakHF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368–80.
22. FerraraN, Davis-SmythT.The biology of vascular endothelial growth factor. Endocr Rev 1997;18(1):4–25.
23. KendallRL, WangG, ThomasKA.Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226(2):324–8.
24. LevineRJ, LamC, QianC, et al. CPEP Study Group Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355(10):992–1005.
25. VenkateshaS, TorporsianM, LamC, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12(6):642–9.
26. ZhouY, McMasterM, WooK, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160(4):1405–23.
27. ChaiworapongsaT, RomeroR, EspinozaJ, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190(6):1541–7; discussion 1547–50.
28. ShibataE, RajakumarA, PowersRW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90(8):4895–903.
29. BuhimschiCS, NorwitzER, FunaiE, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005;192(3):734–41.
30. LevineRJ, ThadhaniR, QianC, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293(1):77–85.
31. AggarwalPK, JainV, SakhujaV, KarumanchiSA, JhaV.Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 2006;69(3):621–4.
32. SignoreC, MillsJL, QianC, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108(2):338–44.
33. SignoreC, MillsJL, QianC, et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008;28(9):852–8.
34. HertigA, BerkaneN, LeferreG, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50(9):1702–3.
35. ChaiworapongsaT, RomeroR, KimYM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17(1):3–18.
36. WathenKA, TuuttiE, StenmanUH, et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006;91(1):180–4.
37. RanaS, KarumanchiSA, LevineRJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50(1):137–42.
38. VattenLJ, EskildA, NilsenTI, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196(3):239.e1–6.
39. WidmerM, VillarJ, BenigniA, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109(1):168–80.
40. ThomasCP, AndrewsJI, LiuKZ.Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J 2007;21(14):3885–95.
41. SelaS, ItinA, Natanson-YaronS, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008;102(12):1566–74.
42. BillsVL, VaretJ, MillarA, et al. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) 2009;116(3):265–72.
43. WallukatG, HomuthV, FischerT, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103(7):945–52.
44. XiaY, WenH, BobstS, DayMC, KellemsRE.Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003;10(2):82–93.
45. ZhouCC, ZhangY, IraniRA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008;14(8):855–62.
46. FuML, HertitzH, SchulzeW, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000;18(7):945–53.
47. KarumanchiSA, LindheimerMD. Preeclampsia pathogenesis: “triple a rating”-autoantibodies and antiangiogenic factors. Hypertension 2008;51(4):991–2.
48. SpeerPD, PowersRW, FrankMP, et al. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008;198(1):112.e1–7.
49. SavvidouMD, HingoraniAD, TsikasD, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361(9368):1511–17.
50. PoonLC, KametasNA, MaizN, AkolekarR, NicolaidesKH.First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009;53(5):812–18.